Nektar Therapeutics (NKTR) Long-Term Investments (2011 - 2026)

Nektar Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $163.0 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 2001.24% year-over-year to $163.0 million in Q1 2026; TTM through Mar 2026 was $163.0 million, a 2001.24% increase from a year earlier, with the FY2024 full-year figure at $12.2 million, down 52.69% from the prior year.
• Long-Term Investments climbed to $163.0 million in Q1 2026 per NKTR's latest filing, from $5.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $163.0 million in Q1 2026 and bottomed at $4.5 million in Q3 2024.
• The 5-year median for Long-Term Investments is $15.8 million (2024), against an average of $32.1 million.
• Across the five-year window, Long-Term Investments slumped 84.45% in 2022 and soared 2001.24% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $8.9 million in 2022, then surged by 189.26% to $25.8 million in 2023, then tumbled by 52.69% to $12.2 million in 2024, then slumped by 56.04% to $5.4 million in 2025, then soared by 2934.69% to $163.0 million in 2026.
• Per Business Quant, the three latest NKTR Long-Term Investments figures stand at $163.0 million (Q1 2026), $5.4 million (Q2 2025), and $7.8 million (Q1 2025).